Merger

Genmab's $8 billion acquisition of Merus isn't just a deal; it's a bold strategy to own its destiny and dominate the future of oncology therapeutics.

Lument Finance Trust's latest dividend boasts an attractive yield, but recent adjustments raise questions about the health of commercial real estate.

KBRA rates a $328M mortgage trust with significant 'non-prime' loans, signaling a boom in a market segment that balances risk with investor demand.

A rejected $307M Danone offer and claims of poor governance fuel a bitter proxy fight at Lifeway Foods, pitting CEO against her largest shareholder—her brother.

Oak Hill Advisors' record fundraise underscores a major shift in corporate finance, as private credit becomes the go-to capital source for large-cap firms.

Beyond logistics, new AI-powered systems are redefining trust and efficiency in drug development. See how one company is setting a new human-centered standard.

A regulatory filing uncovers a major bank's intricate derivatives strategy in a £2.3bn takeover, raising questions about market transparency.

Hedge fund Balyasny reveals a 1.26% economic stake in Just Group via derivatives, shining a light on the complex strategies at play in its takeover.

Adagio Medical lands ex-Medtronic exec Sean Salmon. His mission: drive its novel cryoablation tech to disrupt the competitive cardiac arrhythmia market.

In the heart of oil country, a new boom is taking shape. New Era Energy & Digital is building a gigawatt-scale AI campus, but can it win the infrastructure race?

Bristol Myers Squibb's Opdivo gets FDA priority review, backed by landmark data suggesting it could unseat a key competitor as the new gold standard.

Bill Ackman's fund posted a stellar 24.1% return. We dive into the high-conviction plays and innovative structure driving this market-beating performance.

BW LPG declared a solid dividend, yet its stock fell. We dissect the numbers, peer strategies, and market forces to see what this reveals about the shipping giant.

The return of a pharma-finance veteran to MediPharm's board isn't just a personnel change; it's a strategic move to secure its global pharmaceutical ambitions.

Bluerock Acquisition Corp. has raised $150 million. With a sector-agnostic mandate, could this new capital pool target the mining industry?

A $3 billion drop in assets at AllianceBernstein, driven by client withdrawals in a flat market, signals a deeper challenge for active asset managers.

With a 2026 launch looming, Nuvalent adds a proven oncology dealmaker to its board, signaling a strategic pivot from R&D to market assault.

Value Added Distributors' purchase of a wire harness maker isn't just a deal; it's a strategic play reshaping the landscape for OEM component suppliers.

The 2025 proxy season saw record director support as investors prioritized financials, yet dissent over executive pay signals a new battleground.

ADP's new retirement plan isn't just about lower fees. It's a tech-driven strategy to solve the SMB benefits gap and empower financial advisors.